311 related articles for article (PubMed ID: 26078000)
1. Noninvasive Imaging of Liposomal Delivery of Superparamagnetic Iron Oxide Nanoparticles to Orthotopic Human Breast Tumor in Mice.
Kato Y; Zhu W; Backer MV; Neoh CC; Hapuarachchige S; Sarkar SK; Backer JM; Artemov D
Pharm Res; 2015 Nov; 32(11):3746-3755. PubMed ID: 26078000
[TBL] [Abstract][Full Text] [Related]
2. Folate-targeted polymeric micelles loaded with ultrasmall superparamagnetic iron oxide: combined small size and high MRI sensitivity.
Hong GB; Zhou JX; Yuan RX
Int J Nanomedicine; 2012; 7():2863-72. PubMed ID: 22745549
[TBL] [Abstract][Full Text] [Related]
3. Superparamagnetic iron oxide nanoparticles conjugated with folic acid for dual target-specific drug delivery and MRI in cancer theranostics.
Huang Y; Mao K; Zhang B; Zhao Y
Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):763-771. PubMed ID: 27770953
[TBL] [Abstract][Full Text] [Related]
4. Dynamic contrast enhanced MRI detects changes in vascular transport rate constants following treatment with thermally-sensitive liposomal doxorubicin.
Fite BZ; Kheirolomoom A; Foiret JL; Seo JW; Mahakian LM; Ingham ES; Tam SM; Borowsky AD; Curry FE; Ferrara KW
J Control Release; 2017 Jun; 256():203-213. PubMed ID: 28395970
[TBL] [Abstract][Full Text] [Related]
5. pH-responsive pHLIP (pH low insertion peptide) nanoclusters of superparamagnetic iron oxide nanoparticles as a tumor-selective MRI contrast agent.
Wei Y; Liao R; Mahmood AA; Xu H; Zhou Q
Acta Biomater; 2017 Jun; 55():194-203. PubMed ID: 28363789
[TBL] [Abstract][Full Text] [Related]
6. Exceedingly small iron oxide nanoparticles as positive MRI contrast agents.
Wei H; Bruns OT; Kaul MG; Hansen EC; Barch M; Wiśniowska A; Chen O; Chen Y; Li N; Okada S; Cordero JM; Heine M; Farrar CT; Montana DM; Adam G; Ittrich H; Jasanoff A; Nielsen P; Bawendi MG
Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2325-2330. PubMed ID: 28193901
[TBL] [Abstract][Full Text] [Related]
7. A superparamagnetic polymersome with extremely high T
Liu Q; Song L; Chen S; Gao J; Zhao P; Du J
Biomaterials; 2017 Jan; 114():23-33. PubMed ID: 27837682
[TBL] [Abstract][Full Text] [Related]
8. Triple Therapy of HER2
Zolata H; Afarideh H; Davani FA
Cancer Biother Radiopharm; 2016 Nov; 31(9):324-329. PubMed ID: 27831759
[TBL] [Abstract][Full Text] [Related]
9. Non-immunogenic dextran-coated superparamagnetic iron oxide nanoparticles: a biocompatible, size-tunable contrast agent for magnetic resonance imaging.
Unterweger H; Janko C; Schwarz M; Dézsi L; Urbanics R; Matuszak J; Őrfi E; Fülöp T; Bäuerle T; Szebeni J; Journé C; Boccaccini AR; Alexiou C; Lyer S; Cicha I
Int J Nanomedicine; 2017; 12():5223-5238. PubMed ID: 28769560
[TBL] [Abstract][Full Text] [Related]
10. Targeting experimental orthotopic glioblastoma with chitosan-based superparamagnetic iron oxide nanoparticles (CS-DX-SPIONs).
Shevtsov M; Nikolaev B; Marchenko Y; Yakovleva L; Skvortsov N; Mazur A; Tolstoy P; Ryzhov V; Multhoff G
Int J Nanomedicine; 2018; 13():1471-1482. PubMed ID: 29559776
[TBL] [Abstract][Full Text] [Related]
11. Effect of PEG molecular weight on stability, T₂ contrast, cytotoxicity, and cellular uptake of superparamagnetic iron oxide nanoparticles (SPIONs).
Park YC; Smith JB; Pham T; Whitaker RD; Sucato CA; Hamilton JA; Bartolak-Suki E; Wong JY
Colloids Surf B Biointerfaces; 2014 Jul; 119():106-14. PubMed ID: 24877593
[TBL] [Abstract][Full Text] [Related]
12. Difference in the intratumoral distributions of extracellular-fluid and intravascular MR contrast agents in glioblastoma growth.
Kim JH; Suh JY; Woo DC; Sung YS; Son WC; Choi YS; Pae SJ; Kim JK
NMR Biomed; 2016 Dec; 29(12):1688-1699. PubMed ID: 27723161
[TBL] [Abstract][Full Text] [Related]
13. Hyaluronan-modified superparamagnetic iron oxide nanoparticles for bimodal breast cancer imaging and photothermal therapy.
Yang RM; Fu CP; Fang JZ; Xu XD; Wei XH; Tang WJ; Jiang XQ; Zhang LM
Int J Nanomedicine; 2017; 12():197-206. PubMed ID: 28096667
[TBL] [Abstract][Full Text] [Related]
14. MRI of breast tumor initiating cells using the extra domain-B of fibronectin targeting nanoparticles.
Sun Y; Kim HS; Park J; Li M; Tian L; Choi Y; Choi BI; Jon S; Moon WK
Theranostics; 2014; 4(8):845-57. PubMed ID: 24955145
[TBL] [Abstract][Full Text] [Related]
15. Extensive preclinical investigation of polymersomal formulation of doxorubicin versus Doxil-mimic formulation.
Alibolandi M; Abnous K; Mohammadi M; Hadizadeh F; Sadeghi F; Taghavi S; Jaafari MR; Ramezani M
J Control Release; 2017 Oct; 264():228-236. PubMed ID: 28844758
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo evaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy.
Mosafer J; Abnous K; Tafaghodi M; Mokhtarzadeh A; Ramezani M
Eur J Pharm Biopharm; 2017 Apr; 113():60-74. PubMed ID: 28012991
[TBL] [Abstract][Full Text] [Related]
17. Exerting Enhanced Permeability and Retention Effect Driven Delivery by Ultrafine Iron Oxide Nanoparticles with T
Wang L; Huang J; Chen H; Wu H; Xu Y; Li Y; Yi H; Wang YA; Yang L; Mao H
ACS Nano; 2017 May; 11(5):4582-4592. PubMed ID: 28426929
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging of tumor angiogenesis using dual-targeting RGD10-NGR9 ultrasmall superparamagnetic iron oxide nanoparticles.
Wu T; Ding X; Su B; Soodeen-Lalloo AK; Zhang L; Shi JY
Clin Transl Oncol; 2018 May; 20(5):599-606. PubMed ID: 28956266
[TBL] [Abstract][Full Text] [Related]
19. Perfusion-guided sonopermeation of neuroblastoma: a novel strategy for monitoring and predicting liposomal doxorubicin uptake
Bellary A; Villarreal A; Eslami R; Undseth QJ; Lec B; Defnet AM; Bagrodia N; Kandel JJ; Borden MA; Shaikh S; Chopra R; Laetsch TW; Delaney LJ; Shaw CM; Eisenbrey JR; Hernandez SL; Sirsi SR
Theranostics; 2020; 10(18):8143-8161. PubMed ID: 32724463
[TBL] [Abstract][Full Text] [Related]
20. Probing and Enhancing Ligand-Mediated Active Targeting of Tumors Using Sub-5 nm Ultrafine Iron Oxide Nanoparticles.
Xu Y; Wu H; Huang J; Qian W; Martinson DE; Ji B; Li Y; Wang YA; Yang L; Mao H
Theranostics; 2020; 10(6):2479-2494. PubMed ID: 32194814
[No Abstract] [Full Text] [Related]
[Next] [New Search]
